Evidence map›Paper›PMID 41648532›Full record

ArticlebioRxiv : the preprint server for biology2026

Lung-Targeting Interleukin-10 mRNA Lipid Nanoparticles Ameliorate Acute Lung Injury.

Yuqin Men, David O Popoola, Yuqi Song, Zhi Cao, Robert Gardner, Rezwana Karim, Chunyan Wang, Nathan Tucker, Robert Cooney, Qinghe Meng and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuqin MenDepartment of Pharmacology, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
David O PopoolaDepartment of Pharmacology, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Yuqi SongDepartment of Surgery, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Zhi CaoDepartment of Pharmacology, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Robert GardnerDepartment of Pharmacology, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Rezwana KarimDepartment of Pharmacology, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Chunyan WangDepartment of Surgery, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Nathan TuckerDepartment of Pharmacology, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Robert CooneyDepartment of Surgery, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Qinghe MengDepartment of Surgery, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.
Yamin LiDepartment of Pharmacology, The State University of New York, Upstate Medical University, Syracuse, NY 13210, USA.ORCID 0000-0002-5535-1807

Funding

Developing sulfonium lipid nanoparticles as a novel platform for mRNA deliveryR35GM160083 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI Yamin Li · 2025 to 2026
$897k
Development of Sulfonium- and Phosphonium-based Cationic Lipid Materials for mRNA DeliveryR03EB032579 · NIBIB · UPSTATE MEDICAL UNIVERSITY · PI LI, YAMIN · 2022 to 2023
$163k
NIBIB NIH HHS R03 EB032579NIGMS NIH HHS R35 GM160083
6 · The paper itself

Abstract

Acute respiratory distress syndrome (ARDS) is the most severe manifestation of acute lung injury (ALI), characterized by diffuse pulmonary inflammation, impaired gas exchange, and high morbidity and mortality. Despite its clinical significance, no specific or effective pharmacological therapies are currently available for its treatment. In this study, we developed a lung-targeted mRNA-sulfonium lipid nanoparticle (mRNA/sLNP) delivery system for the treatment of ALI in a mouse model. We first optimized sulfonium lipid structures, and the optimized sLNP was comprehensively characterized and subsequently loaded with interleukin-10 (IL-10) mRNA. In a lipopolysaccharide (LPS)-induced ALI mouse model, IL-10/sLNP demonstrated both prophylactic and therapeutic efficacy, significantly attenuating pulmonary and systemic inflammation, restoring barrier integrity, and reducing tissue injury.

Indexed as

acute lung injuryIL-10lipid nanoparticleLung-targetingmRNA delivery

Identifiers

PMID41648532
PMCPMC12871830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.